Distribution of molecular breast cancer subtypes in middle eastern-saudi Arabian women: A pilot study

Ultrastructural Pathology

Volumn 33, Issue 4, 2009, Pages 141-150

  Al Tamimi, Dalal M ^a   Bernard, Philip S ^b   Shawarby, Mohamed A ^a   Al Amri, Ali M ^a   Hadi, Maha Abdel ^a  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Breast carcinoma; Gene expression; Immunohistochemical profile; Molecular classification; Supervised analysis; Unsupervised analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CONTROLLED STUDY; ETHNIC AND RACIAL GROUPS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE EAST; OUTCOME ASSESSMENT; PILOT STUDY; POPULATION GENETICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ARABS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SAUDI ARABIA; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 70149116658     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.3109/01913120903183135     Document Type: Article

References (47)

1. Feuer EJ, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst. 1993;85:892-897.
2. Ferlay J, Parkin DM, Pisani P eds. GLOBOCAN: cancer incidence and mortality worldwide. International Agency for Research on Cancer (IARC) Cancer Base 3, IARC Lyon, France 1998.
3. Gulf center for cancer registration, the Research Center; King Faisal Specialist Hospital and research Center. GCC: Breast cancer in the GCC countries 1998-2002. Riyadh (Kingdom of Saudi Arabia): King Faisal Specialist Hospital and Research Center; 2004.
4. Chanrion M, Fontaine H, Rodriguez C, et al. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. BMC Cancer. 2007;7:39.
5. Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology. 2008;52:67-81.
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
7. Van't profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
8. Al-Kuraya K, Schramel P, Skeikh , et al. Predominance of high-grade pathway in breast cancer development of middle east women. Modern Pathology. 2005;18:891-897.
9. Perou CM, Sorlie T, Eisen MB, van de Rijn M, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS. 2001;98:10869-10874.
11. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS. 2003;100:8418-8423.
12. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398.
13. Bertucci F, Finetti P, Cervera N, Maraninchi D, Viens P, Birnbaum D. Gene expression profiling and clinical outcome in breast cancer. OMICS. 2006;10(4):429-443.
14. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
15. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
16. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
17. Jacquemier J, Ginestier C, Rougemont J, Bardou VJ, Charafe-Jauffret E, Geneix J, Adelaide J, Koki A, Houvenaeghel G, Hassoun J, Maraninchi D, Viens P, Birnbaum D, Bertucci F. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;65:767-779.
18. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502.
19. Mullins M, Perreard L, Quackenbush JF, et al. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem. 2007;53:1273-1279.
20. Parker JS, Mullins M, Cheang MCU, et al. A supervised risk predictor of breast cancer based on intrinsic subtypes. JCO. 2009;27(8):1160-1167.
21. Reis-Filho JS, Westbury C, Pierga JY. The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 2006;59:225-231.
22. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 2003;95:14-18.
23. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
24. Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418-427.
25. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA. 2006;103:5923-5928.
26. Megha T, Ferrari F, Benvenuto A, et al. p53 mutant in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol. 2002;55:461-466.
27. Tang P, Wang X, Schiffhauer L, et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci. 2006;36:16-22.
28. Tang P, Wang X, Schiffhauer L, et al. Expression patterns of ER-a, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann Clin Lab Sci. 2006;36:137-143.
29. Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37:127-134.
30. Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-1996.
31. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol. 2006;59:729-735.
32. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple negative breast cancer. Cancer. 2007;109:25-32.
33. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype. A population-based study from the California Cancer Registry. Cancer. 2007;109:1721-1728.
34. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and pcadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;477:688-694.
35. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
36. Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161:1223-1233.
37. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
39. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-4434.
40. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
41. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34.
42. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen receptor-negative breast cancers. Breast Cancer Res. 2007;9:R16.
43. Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-240.
44. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Epidemiology, and end results database. Cancer. 2007;110:876-884.
45. Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohisto-chemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134.
46. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108-118.
47. Bin Amer SN, Magbool Z, Nirmal MS, et al. Gene expression profiling in women with breast cancer in Saudi population. . 2008;29:507-513.